Inventor
ALLAWAY GRAHAM P
US21 patents
⚠️ This page may combine multiple inventors who share the name “ALLAWAY GRAHAM P”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PROGENICS PHARM INC
16 patentsUS6344545B1Feb 5, 2002
Method for preventing HIV-1 infection of CD4+ cells
PROGENICS PHARM INC91 citations97
US6261763B1Jul 17, 2001
Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
PROGENICS PHARM INC38 citations96
US6107019AAug 22, 2000
Method for preventing HIV-1 infection of CD4+ cells
PROGENICS PHARM INC78 citations96
US6034223AMar 7, 2000
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof
PROGENICS PHARM INC69 citations96
US5817767AOct 6, 1998
Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
PROGENICS PHARM INC73 citations96
US7345153B2Mar 18, 2008
Compounds capable of inhibiting HIV-1 infection
PROGENICS PHARM INC23 citations92
US7118859B2Oct 10, 2006
Methods for inhibiting HIV-1 infection
PROGENICS PHARM INC30 citations92
US6972126B2Dec 6, 2005
Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same
PROGENICS PHARM INC33 citations92
US6177549B1Jan 23, 2001
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof
PROGENICS PHARM INC10 citations74
US6083478AJul 4, 2000
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 Immunoconjugates, and uses thereof
PROGENICS PHARM INC9 citations74
US6737267B2May 18, 2004
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof
PROGENICS PHARM INC3 citations63
US7935797B2May 3, 2011
CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion
PROGENICS PHARM INC1 citations52
US7901685B2Mar 8, 2011
Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion
PROGENICS PHARM INC0 citations52
US7862994B2Jan 4, 2011
Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusion
PROGENICS PHARM INC0 citations52
US7858298B1Dec 28, 2010
Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
PROGENICS PHARM INC1 citations52
US6342586B1Jan 29, 2002
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
PROGENICS PHARM INC0 citations52
PANACOS PHARMACEUTICALS INC
4 patentsUS7365221B2Apr 29, 2008
Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
PANACOS PHARMACEUTICALS INC32 citations91
US6605427B2Aug 12, 2003
Assay for detection of viral fusion inhibitors
PANACOS PHARMACEUTICALS INC14 citations83
US6768007B2Jul 27, 2004
Substituted 3′,4′-di-O-camphanoyl-(+)-cis-khellactone analogs, compositions thereof, and methods for using thereof
PANACOS PHARMACEUTICALS INC5 citations62
US7537765B2May 26, 2009
Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
PANACOS PHARMACEUTICALS INC3 citations57